Disease · MONDO_0001569
acoustic neuroma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. acoustic neuroma. Diseases, record MONDO_0001569. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001569
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Vestibular Schwann cell tumor, Vestibular Schwann cell tumour, Vestibular neurinoma, Vestibular neurolemmoma, acoustic neurilemmoma, acoustic neurilemoma, acoustic neurinoma, acoustic schwannoma, neurilemoma, acoustic, neurinoma of the acoustic nerve, neuroma, acoustic, vestibular neurilemmoma, vestibular schwannoma, vestibular schwannoma (disease)
- Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHYLPREDNISOLONE SODIUM SUCCINATE | CHEMBL1201081 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AXITINIB | CHEMBL1289926 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BRIGATINIB | CHEMBL3545311 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CRIZOTINIB | CHEMBL601719 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ICOTINIB | CHEMBL2087361 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOSARTAN | CHEMBL191 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets27
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 4 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ALK | ALK tyrosine kinase receptor | 2 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/238 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 2 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
1 to 10 of 27
See all 27 targetsTrials18
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00863122 | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Early phase 1 | 26 | 2018-11-26 | Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor | LAPATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01767792 | Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas | Phase 2 | 22 | 2020-05-27 | Neurofibromatosis Type 2, Progressive Vestibular Schwannomas | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01207687 | Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) | Phase 2 | 14 | 2017-08-17 | Vestibular Schwannoma, Neurofibromatosis Type 2 | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02129647 | Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Phase 2 | 13 | 2021-12-01 | Neurofibromatosis Type 2, Vestibular Schwannomas | AXITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04283669 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Phase 2 | 12 | 2026-03-13 | Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) | CRIZOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors | Phase 2 | 10 | 2025-04-22 | Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma | SELUMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02282917 | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | Early phase 1 | 7 | 2022-05-11 | Vestibular Schwannoma, Meningioma, Acoustic Neuroma, Neurofibromatosis Type 2 | AR-42 | Its record names the disease | ClinicalTrials.gov |
| NCT07116811 | Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients | Phase 3 | 364 | Vestibular Schwannoma, Facial Nerve Paralysis | METHYLPREDNISOLONE SODIUM SUCCINATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | Phase 2 | 109 | Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma | BRIGATINIB, NERATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03079999 | Study of Aspirin in Patients With Vestibular Schwannoma | Phase 2 | 97 | Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2 | ASPIRIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment (Bevacizumab) - All Participants vs Treatment (Bevacizumab) - Pediatric Participants: Incidence of Serious or Life Threatening Toxicities | 2 of 14 | 0 of 2 | 16 | NCT01207687 | Trial comparisons |
| Treatment (Bevacizumab) - All Participants vs Treatment (Bevacizumab) - Pediatric Participants: deaths from any cause | 0 of 14 | 0 of 2 | 16 | NCT01207687 | Trial comparisons |
| Treatment (Bevacizumab) - All Participants vs Treatment (Bevacizumab) - Pediatric Participants: serious adverse events | 2 of 14 | 0 of 2 | 16 | NCT01207687 | Trial comparisons |
| Lapatinib vs Control: Assess the Level of ErbB2 Phosphorylation in VS. | 5 of 9 | 2 of 4 | 13 | NCT00863122 | Trial comparisons |
| Stratum 1: NF2 Tumor (Vestibular Schwanomas) vs Stratum 2- NF2 Tumors (Non-vestibular Schwanoma (VS)): Radiographic Tumor Response | 1 of 1 | 9 of 9 | 10 | NCT03095248 | Trial comparisons |
| Stratum 1 - NF2 Related Vestibular Schwannomas vs Stratum 2: Other NF2 Related Tumors (Meningiomas and Ependymoma): deaths from any cause | 0 of 1 | 0 of 9 | 10 | NCT03095248 | Trial comparisons |
| Stratum 1 - NF2 Related Vestibular Schwannomas vs Stratum 2: Other NF2 Related Tumors (Meningiomas and Ependymoma): serious adverse events | 1 of 1 | 2 of 9 | 10 | NCT03095248 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001569
GET https://conductscience.org/api/diseases/v1/MONDO_0001569/targets?page=2